99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
1998

99mTc-sestamibi and Multidrug Resistance in Cancer Cells

publication Evidence: moderate

Author Information

Author(s): NH Hendrikse, EJF Franssen, WTA van der Graaf, C Meijer, DA Piers, W Vaalburg, EGE de Vries

Primary Institution: University Hospital Groningen

Hypothesis

99mTc-sestamibi is a substrate for the multidrug resistance-associated protein (MRP) pump.

Conclusion

The study shows that 99mTc-sestamibi is involved in MRP-mediated efflux, which affects its concentration in cancer cells.

Supporting Evidence

  • 99mTc-MIBI concentration decreased in doxorubicin-resistant cell lines with increasing MRP overexpression.
  • Co-incubation with vincristine increased 99mTc-MIBI concentration in GLC4 lines.
  • Glutathione depletion elevated 99mTc-MIBI concentration in resistant cell lines.

Takeaway

This study found that a substance called 99mTc-sestamibi can be pushed out of cancer cells by certain proteins, making it harder for the drug to work.

Methodology

The study evaluated 99mTc-MIBI in various cancer cell lines with different levels of drug resistance and measured its accumulation and efflux.

Limitations

The study primarily focused on in vitro experiments, which may not fully represent in vivo conditions.

Statistical Information

P-Value

p<0.0005

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication